Melanoma | Patterns of Care: Optimizing the Current Management of Melanoma with BRAF Mutation in the Real World

published 6 months ago by Dr Neil Love

Featuring a roundtable discussion with Drs Adil Daud, Michael Postow, Hussein Tawbi and Jeffrey S Weber on the following topics: Metastatic Disease Introduction Case: A woman in her early 50s with Stage IV melanoma and a solitary brain metastasis Case: A man in his early 20s with metastatic melanoma with a BRAF mutation and CNS metastases Case: A woman in her mid-80s with metastatic melanoma with a BRAF mutation who received encorafenib/binimetinib Case: A man in his early 60s with widespread metastatic melanoma Case: A man in his mid-80s with metastatic melanoma with a BRAF mutation and a PD-L1 CPS (combined positive score) of 10% Available evidence and ongoing research with the combination of BRAF/MEK inhibitors and immunotherapy for advanced melanoma with a BRAF mutation Assessment of PD-L1 level in deciding on first-line therapy for patients with metastatic melanoma First-line therapy options for younger patients with metastatic melanoma with BRAF mutations Case: A woman in her early 50s with melanoma with a BRAF mutation and brain metastases Case: A man in his mid-70s with metastatic melanoma with a BRAF mutation Similarities and differences among BRAF/MEK inhibitor combinations (dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib) used in the treatment of metastatic melanoma with a BRAF mutation Effects of the COVID-19 pandemic on the clinical care of patients with melanoma Case: A man in his mid-20s with newly diagnosed metastatic melanoma with a BRAF V600E mutation Case: A woman in her late 40s with metastatic melanoma with a BRAF mutation Thresholds for dose reduction and delay with dabrafenib/trametinib, vemurafenib/cobimetinib and encorafenib/binimetinib Adjuvant Systemic Therapy Case: A man in his early 70s with Stage IIIC melanoma and diabetes Case: A woman in her early 50s with melanoma with a high tumor mutation burden Case: A woman in her mid-60s with Stage IIIC melanoma with a BRAF V600E mutation Use of encorafenib/binimetinib or vemurafenib/cobimetinib as adjuvant therapy Potential contraindications for immune checkpoint inhibitors (eg, prior autoimmune disease, transplant) Case: A woman in her early 50s with localized melanoma and a BRAF V600E mutation Case: A woman in her early 70s with localized melanoma and a BRAF V600E mutation; duration of adjuvant therapy with BRAF/MEK combinations Case: An otherwise healthy man in his early 30s with localized melanoma and a BRAF V600K mutation CME information and select publications

more episodes from Research To Practice | Oncology Videos